

Olav Dalgard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9321769/publications.pdf>

Version: 2024-02-01

55
papers

6,067
citations

236612

25
h-index

143772

57
g-index

61
all docs

61
docs citations

61
times ranked

7851
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
2	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018, 69, 461-511.	1.8	1,489
3	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	1.9	333
4	Elbasvirâ€“Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. <i>Annals of Internal Medicine</i> , 2016, 165, 625.	2.0	322
5	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	3.7	231
6	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
7	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1028-1038.	1.6	159
8	HCV epidemiology in high-risk groups and the risk of reinfection. <i>Journal of Hepatology</i> , 2016, 65, S33-S45.	1.8	146
9	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	3.7	128
10	Hepatitis C reinfection after sustained virological response. <i>Journal of Hepatology</i> , 2016, 64, 1020-1026.	1.8	122
11	IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. <i>Hepatology</i> , 2011, 53, 746-754.	3.6	118
12	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018, 68, 402-411.	1.8	105
13	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 643-657.	1.8	103
14	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019, 39, 20-30.	1.9	88
15	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	2.0	84
16	A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. <i>Nature Communications</i> , 2020, 11, 5284.	5.8	66
17	Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. <i>Journal of Hepatology</i> , 2016, 64, 19-28.	1.8	60
18	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	1.6	58

#	ARTICLE	IF	CITATIONS
19	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
20	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, e115-e124.	2.9	53
21	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , 2019, 69, 2218-2227.	2.9	52
22	Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0166451.	1.1	34
23	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. <i>Journal of Clinical Virology</i> , 2017, 92, 32-38.	1.6	32
24	Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). <i>PLoS Medicine</i> , 2021, 18, e1003653.	3.9	29
25	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 230-238.	1.6	28
26	Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). <i>BMC Infectious Diseases</i> , 2019, 19, 943.	1.3	28
27	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections—A Scandinavian real-life study. <i>PLoS ONE</i> , 2017, 12, e0179764.	1.1	28
28	Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study. <i>Journal of Hepatology</i> , 2014, 60, 260-266.	1.8	26
29	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	2.9	26
30	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	1.6	22
31	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2369-2376.	2.9	19
32	Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. <i>BMC Infectious Diseases</i> , 2019, 19, 955.	1.3	15
33	Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, 1101-1103.	1.8	14
34	Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973–2030. <i>BMC Infectious Diseases</i> , 2017, 17, 541.	1.3	14
35	Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. <i>International Journal of Drug Policy</i> , 2021, 96, 103165.	1.6	14
36	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 177-186.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway. <i>Pharmacoeconomics</i> , 2018, 36, 591-601.	1.7	13
38	Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1177-1189.	1.0	12
39	In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 552-556.	0.8	10
40	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2016, 11, e0155142.	1.1	10
41	Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. <i>Journal of Internal Medicine</i> , 2022, 291, 241-243.	2.7	9
42	Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. <i>PLoS ONE</i> , 2018, 13, e0190146.	1.1	9
43	Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. <i>Liver International</i> , 2022, 42, 1268-1277.	1.9	9
44	Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 485.	0.7	7
45	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	1.3	6
46	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. <i>Journal of Hepatology</i> , 2019, 70, e733.	1.8	5
47	Increased hope following successful treatment for hepatitis C infection. <i>Journal of Advanced Nursing</i> , 2018, 74, 724-733.	1.5	3
48	Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. <i>PLoS ONE</i> , 2021, 16, e0253710.	1.1	3
49	The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection. <i>PLoS ONE</i> , 2015, 10, e0120866.	1.1	2
50	Impact of liver fibrosis and clinical characteristics on dose-adjusted serum methadone concentrations. <i>Journal of Addictive Diseases</i> , 2023, 41, 53-63.	0.8	2
51	Debilitating fatigue as a treatment indication in chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 63, 1533-1534.	1.8	1
52	The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1172-1175.	0.6	1
53	Hepatitis C in Iceland: a milestone for global elimination. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 599-600.	3.7	1
54	Hepatitis C reinfection in former and active injecting drug users in Belgium. <i>Harm Reduction Journal</i> , 2021, 18, 102.	1.3	1

#	ARTICLE	IF	CITATIONS
55	Recommandations pour la prise en charge de l'™infection par le virus de l'™h©patite C chez les usagers de drogues par injection. International Journal of Drug Policy, 2015, , 101669.	1.6	0